Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib Combined With Aspirin as First-line Treatment for EGFR-positive NSCLC
NCT04184921Phase 2Completed
- Start
- Jan 2019
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of aspirin in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Progression-Free Survival at 5 years. Started Jan 2019; status: completed.
02
Drugs
aspirin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04184921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04184921.